{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:44:45Z","timestamp":1791805485826,"version":"4.3.4"},"reference-count":34,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is a rare and severe condition that may be associated with exposure to certain drugs. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has been classified as having a possible association with PAH, but data remain scarce. This study aimed to assess the potential link between bevacizumab exposure and PAH through complementary clinical, medico-administrative and pharmacovigilance databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a multimodal investigation combining: 1) case identification from the French Pulmonary Hypertension (PH) Registry, 2) a population-based cohort analysis using the French National Health Data System (Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS)) and 3) a disproportionality analysis in the World Health Organization pharmacovigilance database (VigiBase). Clinical, haemodynamic and exposure data were reviewed in the French PH Registry; prevalence of PAH in patients exposed to bevacizumab was computed in the SNDS; and disproportionality analyses (information component (IC) values) were calculated in VigiBase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven cases of PAH temporally associated with bevacizumab were identified in the French PH Registry, most displaying predisposing conditions (\n                      <jats:italic>BMPR2<\/jats:italic>\n                      mutation, portal hypertension or COPD). In the SNDS cohort of 9964 PAH patients, 30 had prior bevacizumab exposure, with no increased incidence compared to the general population. In VigiBase, 21 PAH cases were reported with bevacizumab, yielding a modest disproportionality signal only under broad definitions (IC 0.4 (95% credibility interval 0.1\u20130.6)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across complementary data sources, there was no evidence of a causal association between exposure to bevacizumab and the development of PAH in adults. However, the effect of bevacizumab as a secondary trigger in predisposed individuals cannot be definitely or completely excluded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00209-2026","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:00:26Z","timestamp":1776358826000},"page":"00209-2026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal investigation of the association between bevacizumab and pulmonary arterial hypertension"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-1359","authenticated-orcid":false,"given":"Simon","family":"Valentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8483-5023","authenticated-orcid":false,"given":"Alex","family":"Hlavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6333-5674","authenticated-orcid":false,"given":"Coline","family":"Brossat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1217-8442","authenticated-orcid":false,"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Artaud-Macari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mauran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Maurac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-1951","authenticated-orcid":false,"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-202X","authenticated-orcid":false,"given":"Ari","family":"Chaouat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-8573","authenticated-orcid":false,"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026101203450751000_12.5.00209-2026.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2000348"},{"key":"2026101203450751000_12.5.00209-2026.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324-2024"},{"key":"2026101203450751000_12.5.00209-2026.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"2026101203450751000_12.5.00209-2026.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1601"},{"key":"2026101203450751000_12.5.00209-2026.5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-6-713"},{"key":"2026101203450751000_12.5.00209-2026.6","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0343com"},{"key":"2026101203450751000_12.5.00209-2026.7","first-page":"4848","article-title":"The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function","volume":"6","author":"Mendel","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2026101203450751000_12.5.00209-2026.8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jamaophthalmol.2022.3788","article-title":"Pulmonary hypertension in preterm infants treated with laser vs anti-vascular endothelial growth factor therapy for retinopathy of prematurity","volume":"140","author":"Nitkin","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"2026101203450751000_12.5.00209-2026.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"2026101203450751000_12.5.00209-2026.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.08.003"},{"key":"2026101203450751000_12.5.00209-2026.11","doi-asserted-by":"crossref","first-page":"A2452","DOI":"10.1016\/j.chest.2022.08.2009","article-title":"A case of bevacizumab-associated pulmonary hypertension","volume":"162","author":"Sekar","year":"2022","journal-title":"Chest"},{"key":"2026101203450751000_12.5.00209-2026.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2026101203450751000_12.5.00209-2026.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2026101203450751000_12.5.00209-2026.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2026101203450751000_12.5.00209-2026.15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00109-2024"},{"key":"2026101203450751000_12.5.00209-2026.16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2026101203450751000_12.5.00209-2026.17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19427"},{"key":"2026101203450751000_12.5.00209-2026.18","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466"},{"key":"2026101203450751000_12.5.00209-2026.19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40264-018-00792-0","article-title":"A comparison study of algorithms to detect drug\u2013adverse event associations: frequentist, Bayesian, and machine-learning approaches","volume":"42","author":"Pham","year":"2019","journal-title":"Drug Saf"},{"key":"2026101203450751000_12.5.00209-2026.20","doi-asserted-by":"crossref","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","article-title":"Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events","volume":"13","author":"Montes-Grajales","year":"2023","journal-title":"Sci Rep"},{"key":"2026101203450751000_12.5.00209-2026.21","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"2026101203450751000_12.5.00209-2026.22","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15436"},{"key":"2026101203450751000_12.5.00209-2026.23","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00130-6"},{"key":"2026101203450751000_12.5.00209-2026.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04229-2020"},{"key":"2026101203450751000_12.5.00209-2026.25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.202504-1024IM","article-title":"Diagnosing pulmonary tumor thrombotic microangiopathy using pulmonary microvascular cytology","volume":"212","author":"le Camus","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101203450751000_12.5.00209-2026.26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00395-020-0811-5","article-title":"Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension","volume":"115","author":"Winter","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"2026101203450751000_12.5.00209-2026.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01110-2015"},{"key":"2026101203450751000_12.5.00209-2026.28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2026101203450751000_12.5.00209-2026.29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15842"},{"key":"2026101203450751000_12.5.00209-2026.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2026101203450751000_12.5.00209-2026.31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41372-022-01489-0","article-title":"Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension","volume":"43","author":"Park","year":"2023","journal-title":"J Perinatol"},{"key":"2026101203450751000_12.5.00209-2026.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01576-2021"},{"key":"2026101203450751000_12.5.00209-2026.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"2026101203450751000_12.5.00209-2026.34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis","volume":"49","author":"Fusaroli","year":"2026","journal-title":"Drug Saf"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00209-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:45:16Z","timestamp":1791801916000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00209-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.00209-2026"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00209-2026","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}